ARS Pharmaceuticals, Inc. SPRY Operating Cash Flow
Operating Cash Flow at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s operating cash flow.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s operating cash flow?
- ARS Pharmaceuticals, Inc. (SPRY) reported operating cash flow of -$44.95M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s operating cash flow changed year-over-year?
- ARS Pharmaceuticals, Inc.'s operating cash flow decreased by 10.3% year-over-year, from -$40.74M to -$44.95M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s operating cash flow?
- Over 3 years (2022 to 2025), ARS Pharmaceuticals, Inc.'s operating cash flow has grown at a 62.1% compound annual growth rate (CAGR), from -$40.08M to -$170.87M.
- What does operating cash flow mean?
- Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.